

Title: Retina Update 2024 and Beyond

Author: Jeffry D. Gerson, OD, FAAO

Summary: With so many advancements over the last 18 months and even more expected over the next 24 months, it is hard to keep track of what is available to our patients and our practices. This course will not only go over newer technologies/treatments that are already available but also those that may be coming. Time will be spent to put these changes into perspective and how they fit into our practices in a practical way.

Goals:

1. Discuss treatments that are newly approved in retina care and how they affect patients and practices.
2. Discuss treatments and technologies in the retina pipeline that we should know about before they get to market.
3. Become familiar with conditions that have new treatments in a way to be able to explain to patients.

Outline:

Direct to consumer marketing

- Retina companies with TV commercials
- Influence on patients and their inquiries
- Influence on doctors and need for knowledge

Photobiomodulation

- Definition of PBM
 - Specific wavelengths for specific conditions
 - Science behind
- Conditions in which it can/may be able to be used
 - Ocular
 - Non-ocular
- PBM in macular degeneration
 - LightSite 1
 - LightSite 3
 - Efficacy and safety results
- Use in Europe and other countries

AI in retina

- Digital image capture and interpretation
- Levels of interpretation and usefulness
- AI in eyecare in general and how it can relate to retina
 - AI to help get to a diagnosis
- Approved devices/algorithms in diabetes
 - Fundus camera add-on
 - Hand held portable instrument
 - Billing implications
 - Implications to primary care

Does this constitute an eye exam?

HEDIS

Digital Home monitoring

Foresee Home

HOME study

Aloft study

Scanly

Studies for US approval

Implications for AMD treatment

TXE vs metrics based

GA treatment

Complement cascade

Complement inhibition

C3

C5

Vitamins in AMD

AREDS2 10 year

AREDS2 for GA

Melatonin and AMD

Biosimilar

Definition

General medicine

Retina

Efficacy

Cost

RegenexBIO

Adeno-associated viral vectors

Genetic “engineering” for treatment

Altering gene expression without causing disease

Extended duration

Anti-VEGF injections

Increased concentration of “old” drug

Bi-Specific molecules

More than one pathway

Longer duration leading to less burden

Port

SUSVIMO

Approval/removal/approval

Efficacy

Alternate delivery of Anti-VEGF

Oral

Topical

Stem Cells

No FDA approved treatment for retinal disease with stem cells

NEI study ongoing

Potential finish date and implications

Tricor for NPDR

Studies leading to approval in Europe/Australia

Outcomes and decrease in need for more treatment

When to initiate

DRCR ongoing study